The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
about
Topical pimecrolimus as a new optional treatment in cutaneous sarcoidosis of lichenoid typeDexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cellsInfluence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.Calcineurin inhibitors and rapamycin: cancer protection or promotion?International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies.The role of T cells in psoriasis.Therapeutic potential of macrolide immunosuppressants in dermatology.Pimecrolimus for the treatment of inflammatory skin disease.Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In VitroMacrolactam immunomodulators (tacrolimus and pimecrolimus): new horizons in the topical treatment of inflammatory skin diseases.Pimecrolimus -- an anti-inflammatory drug targeting the skin.Problem-based learning: a review of current issues relevant to physiotherapy education.Atopic eczema: what's new?Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.Systemic ciclosporin and tacrolimus in dermatology.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.Two cases of telangiectasia macularis eruptiva perstans demonstrated by immunohistochemistry for c-kit (CD 117).Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial.Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells.Pimecrolimus reduces eosinophil activation associated with calcium mobilization.Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial.[Development and pre-clinical aspects of pimecrolimus].[Antipruritic effects of pimecrolimus and tacrolimus].Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids.Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment.[Efficacy of tracrolimus 0.1% ointment in prurigo].Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%.Phenotypic variability in human skin mast cells.Long-term cultured human skin mast cells are suitable for pharmacological studies of anti-allergic drugs due to high responsiveness to FcεRI cross-linking.
P2860
Q33552277-ABB5B6B3-0BB3-4064-B8FE-0A23C417A4FFQ33669494-60EA640F-1385-4CCA-87A5-AA180A2EC7A4Q34552586-46D3DB94-C10A-4D6B-B505-51A183B530C7Q34578721-F5D77F8D-0A02-4159-A29F-46CD12B7B370Q35106685-2684E2CA-8945-44C9-A411-5D92F4FCBA4BQ35110104-A0682C0C-6530-4E10-AA3F-C1E28989189DQ35680649-F65A17F0-0531-483D-9B3A-C9A0460466E9Q35688189-EF5B6B5D-A03F-4636-968F-CA2F2DD97729Q35839772-CC93BABE-7971-4576-B645-A8FC1D015147Q35922000-6027D703-0876-433C-9D92-739DB509E180Q35961095-DE6C90F7-4E58-4C0E-A08C-B06D9BDFFC6DQ36356956-2B5F678E-1EF5-431F-8B82-CC35EF742DADQ36473293-A3E39745-64C2-4DE4-A57B-26A02EAAD969Q36574341-249467CE-50C2-4416-91A4-8A215D4680C3Q36681795-D87A7F3F-1298-4CC7-8B26-0C2D5DDBC45EQ36986032-B45A70EF-FB09-4C25-A68C-DFF2D3933C56Q38123240-6DC239C3-268D-4A31-B934-81356EB7A5D3Q38511839-B4F40977-18E7-47A8-B74D-FFD25EFE0917Q38536150-BEDB43ED-B7DC-481D-9AC8-0A9AEE9A2FB0Q39332348-8293DE3A-E418-4E89-9BB0-CE2B7AEA28C4Q39355978-71217B5B-56A3-45F5-8C46-4F9896FD0AA8Q40518398-42E9713D-B4DE-4B66-9FB0-4DCBA06F1DFEQ42643465-EDA4D007-85E6-4BDF-B8EC-D1CF56D26A7BQ42668620-75DEE1B2-0535-4BBC-BF03-2BFA14BA2829Q44420839-A7AE8808-5F9D-48F6-92C2-BE4172DE2C75Q44420847-6C113D4B-2EBC-4DDD-8E3D-9CCB0EB422D9Q44557361-58E5C27D-3985-405E-801C-BAF657AAB59DQ46494876-C062784B-4894-4452-A248-7B3A9668E0A5Q46521069-78C710E3-07C0-41AE-93E3-C5A12E1DEFC4Q46524678-C033E4A8-012B-477A-B091-FE63FA878499Q46712893-95591696-0FC5-4D50-B5E0-254234772DACQ46817775-DB40F5B0-FF15-406B-9244-5B5D0A1DCA44Q46892555-FA5653B1-1CDF-4E6D-9A23-1F2B0D7668CCQ52898246-2353CFCC-FCE4-424A-B2A7-97838A51EB86
P2860
The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@en
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@nl
type
label
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@en
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@nl
prefLabel
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@en
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@nl
P2093
P356
P1476
The ascomycin macrolactam pime ...... nd peripheral blood basophils.
@en
P2093
P304
P356
10.1067/MAI.2001.116865
P407
P577
2001-08-01T00:00:00Z